Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...

Gene Holdings ( ($ENGN) ) has issued an announcement. enGene Holdings Inc. has reported promising preliminary data from its Phase 2 LEGEND trial ...

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

A phase 3 trial supports durvalumab added to BCG induction and maintenance therapy as a potential new treatment for BCG-naïve, high-risk NMIBC. Adding durvalumab to Bacillus-Calmette-Guerin (BCG) ...